Publikationen, an denen er mitarbeitet Jesús María Prieto Valtueña (77)

2017

  1. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  2. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Cytokines for the treatment of gastrointestinal cancers: Clinical experience and new perspectives

    Expert Opinion on Investigational Drugs, Vol. 22, Núm. 7, pp. 827-841

  3. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  4. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087

  5. Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure

    PLoS ONE, Vol. 8, Núm. 1

2011

  1. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma

    Functional and Integrative Genomics, Vol. 11, Núm. 3, pp. 419-429

  2. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  3. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages

    Annals of Surgical Oncology, Vol. 18, Núm. 7, pp. 1964-1971

  4. Transarterial therapies for hepatocellular carcinoma

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 7, pp. 1057-1073

2010

  1. A phase i clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

    Cancer Gene Therapy, Vol. 17, Núm. 12, pp. 837-843

  2. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma

    International Journal of Radiation Oncology Biology Physics, Vol. 77, Núm. 5, pp. 1441-1448

  3. Gene therapy for liver cancer: Clinical experience and future prospects

    Current Opinion in Molecular Therapeutics, Vol. 12, Núm. 5, pp. 561-569

2009

  1. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma

    Hepato-Gastroenterology, Vol. 56, Núm. 96, pp. 1683-1688

  2. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report

    Clinical Transplantation, Vol. 23, Núm. 4, pp. 532-536

  3. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy

    Cancer Research, Vol. 69, Núm. 4, pp. 1358-1367